Biotechnology & Pharmaceutical Opptys

An Expert's View about Medical, Health and Cosmetics Products in Singapore

Last updated: 21 Aug 2011

Singapore embarked on its Biomedical Sciences (BMS) initiative in 2000 to develop the pharmaceuticals, biotechnology, medical technology and healthcare sectors, as part of its move to a knowledge based economy.

Sector briefing Biotechnology & Pharmaceutical Opportunities in Singapore Why Singapore? Singapore embarked on its Biomedical Sciences (BMS) initiative in 2000 to develop the pharmaceuticals, biotechnology, medical technology and healthcare sectors, as part of its move to a knowledge based economy. Since then, the BMS sector has grown rapidly, and it is now the second-largest manufacturing cluster, with nearly 90% of the output from pharmaceuticals, followed by medical devices. The manufacturing sector contributes to a quarter of Singapore?s economy. Singapore aims to grow its BMS output to £12.5 billion by 2015, which is well on track with ongoing public and private sector Singapore aims to grow its investment. Biomedical Sciences output to £12.5 billion by 2015. Singapore was rated among the world?s top 5 biotech spots by Fiercemonitor, in 2007. Find general information on the Singapore market conditions on UKTI?s website. The Doing Business Guide for Singapore gives an overview of Singapore?s economy, business culture, potential opportunities and an introduction to other relevant issues. UK Trade & Investment Sector briefing: Biotech & Pharmaceutical opportunities in Singapore invest £1.8 billion in BMS research from 2011- Opportunities 2015, a 12% increase over 2006-2010. The key focus will be better integration of research The BMS sector is driven by three key bodies, performers across the BMS landscape; greater the Agency for Science, Technology and emphasis on translational and clinical research Research (A*STAR), the Economic (TCR); and stronger focus on economic Development Board (EDB), and the Ministry of outcomes. Health (MOH), with high level advisory committees to chart its course. The biomedical The BMS Industry Partnership Office (IPO), was city, Biopolis, now in its phase IV, locates set up in 2010 to better integrate research public and private R&D centres, while Tuas efforts, and as a one stop shop for BMS Pharma Park offers shared facilites for companies that wish to engage multiple pharmaceutical manufacturers. A medical Singapore agencies in research collaborations. technology cluster in the west will be developed to accelerate its growth. Pharmaceuticals There are now 12 global pharmaceutical and Leading pharmaceutical companies such as biotechnology companies in Singapore who GlaxoSmithKline, Merck Sharp & Dohme, have invested in over 25 commercial- Schering-Plough, Wyeth, Pfizer, Abbott, manufacturing facilities. Another seven plants Novartis, Lonza have set up large scale are set to open in the next three years. The manufacturing facilities in Singapore. Fixed BMS sector was predicted to grow between 5 - asset investments reached £0.6 billion in 2009. 10% in 2010. Total output stood at £10.5 Following large scale investment from API billion in 2009, accounting for 10% of total manufacturers, Singapore is now focusing on manufacturing output. biologics, and has attracted US$2 billion worth of investments in the last four years, for 6 new Over 100 global biomedical sciences companies plants. have leveraged on Singapore?s world class manufacturing capabilities, clinical and A number of pharmaceutical MNCs also have scientific infrastructure, connectivity to Asian their Asia Pacific HQ in Singapore. Besides markets and pro-business environment to carry sales, marketing and distribution, they also out a range of activities from cutting-edge undertake R&D, and six new R&D bases were research and clinical trials, to manufacturing established in 2009. They also partner and regional headquarters in Singapore. Singapore?s multi-disciplinary scientific and clinical network to develop new drugs and R&D therapies resulting in 3 key industry partnerships in 2010. A new national research structure was set up in 2006, with the Research, Innovation and Biotechnology Enterprise Council chaired by the Prime Minister, under the new National Research Considerable investment has been made to Foundation. NRF allocated £2.5 billion over 5 nurture and grow the sector. While BMS Phase years for 3 targeted sectors: biomedical 1 focused on basic science and Phase 2 on sciences, environment and water technologies, moving research from the bench to the and interactive and digital media. R&D funds bedside, phase 3 is aimed at greater from NRF, A*STAR and the Ministry of Health integration across agencies, disciplines and the are primarily channelled to research into areas industry to achieve greater economic impact. such as oncology, eye diseases, infectious The public sector research institutes are diseases, and medical devices. Other R&D increasingly collaborating with universities and programmes to spur life sciences research hospitals in their translational medicine efforts. include The Translational Clinical Research The main areas of research are stem cells, programme run by the National Medical oncology, immunology, neurology, metabolic Research Council, and the Clinician-Scientist disorders, and infectious diseases. The Award, among others. research institutes are helmed by renowned international scientists and are staffed by There are over 4,300 researchers engaged in skilled local and international scientists. BMS R&D in 50 companies and 30 public sector institutes, with an annual R&D budget of around £0.5 billion. The government will UK Trade & Investment Sector briefing: Biotech & Pharmaceutical opportunities in Singapore There is also a growing number of local biotech New Projects companies involved in stem cell research, drug discovery and diagnostics. The BMS landscape in Singapore is dynamic and continues to draw in new players while Medical Technology current companies expand their footprint. Some recent developments include: There are around 60 medtech companies, mainly MNCs, manufacturing a range of ? Six new biologics manufacturing products such as syringes, catheters, hearing facilities at around £1 billion to open aids, contact lenses, stents, pace makers, from 2011 onwards. research instruments and scientific analytical ? New/expansion of pharmaceutical plants equipment. Several leverage on the scientific ? New research labs by pharmaceutical and engineering capabilities available in manufacturers and medical devices Singapore to develop innovative and cost companies effective products for the Asian markets. ? New regional headquarters by MNCs for the Asia Pacific market. Singapore accounts for 10% of the world?s ? New plants by cardiac products supply of contact lenses, half of the world?s manufacturers. thermal cyclers, and over 50% of the world?s ? New set ups and expansion by clinical micro arrays. The medtech industry trials companies manufacturing target is £2.5 billion by 2012. ? New set ups by international companies There is also a strong supporting local industry that supply a range of products, in electronics and precision manufacturing. equipment and services to the entire In a concerted effort to grow the medtech BMS industry. industry, £18 million was allocated for scientists to work with universities and If you have any questions on the opportunities hospitals to develop medical devices such as above, contact the UKTI contacts named in this heart stents, pacemakers, diagnostics for report. Business opportunities aimed stroke and glaucoma, better catheters etc. £10 specifically at UK companies are added daily to million was awarded for research projects in UKTI?s website. These leads are sourced by our November 2009. staff overseas in British Embassies, High Commissions and Consulates, across all sectors Clinical Trials and in over 100 markets. The Asian clinical trial market is expected to You can be alerted to business opportunities on grow by 20%, and Singapore aims to be the a regular basis by registering on the UKTI regional centre for clinical trials and drug website. Find out more on UKTI?s business development. opportunities service on the UKTI website. Major CROs such as Quintiles, Covance, MDS Pharma, PPD, Icon etc are established and expanding in Singapore, to address the growing Asian market. Singapore offers a strategic location in Asia to access a diverse patient base, efficient logistics, Government commitment to the life sciences sector, skilled investigators and manpower, and a good regulatory environment to ensure patient safety during clinical trials. Singapore was ranked as one of the most competitive countries globally for conducting world class research in a 2006 survey by KPMG, the only Asian country besides Japan. UK Trade & Investment Sector briefing: Biotech & Pharmaceutical opportunities in Singapore Major events and activities UKTI contacts Biopharma Asia Conference & Exhibition Ms Valsa Panicker http://www.terrapinn.com/2012/biophar Senior Trade & Investment Attache ma-asia-convention-conference/ British High Commission Singapore Contact: Valsa Panicker Tel: (0065) 64244 200 Email: Valsa.Panicker@fco.gov.uk Email: Valsa.Panicker@fco.gov.uk Time: 19 ? 22 March 2012 www.ukti.gov.uk Interphex Asia Exhibition Sarah Croft www.interphexasia.com First Secretary Contact: Valsa Panicker British High Commission Singapore Email: Valsa.Panicker@fco.gov.uk Tel: (0065) 64244 200 Time: May 2012 (dates awaited) Email: Sarah.Croft@fco.gov.uk www.ukti.gov.uk There are also regular life sciences seminars by various organisers throughout the year. Find full details of all events in this country and sector on the UKTI website. New export events are added daily to the site and you can register to be alerted to them on a daily, weekly or monthly basis UKTI?s Tradeshow Access Programme (TAP) provides grant support for eligible Small & Medium Sized Enterprises (SME's) to attend trade shows overseas. Find out more about UKTI support for attendance at overseas events. UK Trade & Investment Sector briefing: Biotech & Pharmaceutical opportunities in Singapore Next steps - How UKTI can help ? Arranging appointments British companies wishing to develop their ? Organise seminars or other events for business in the Singapore market are advised you to meet contacts and promote your to undertake as much market research and company in the Singaporean market planning as possible. UKTI?s team in Singapore, with its local knowledge and This work is available via our Overseas Market experience, can provide a range of services to Introduction Service (OMIS) a chargeable British-based companies wishing to grow their service which assists British-based companies business in Singapore. wishing to enter or expand their business in overseas markets. This can include: ? Provision of market information To find out more about commissioning this ? Validated lists of agents/distributors work, or accessing other UKTI services and ? Key market players or potential specialist advice, please visit the UKTI website customers in the Singaporean market to find contact details for your local UKTI ? Establishment of interest of such office. contacts in working with you Whereas every effort has been made to ensure that the information given in this document is accurate, neither UK Trade & Investment nor its parent Departments (the Department for Business, Innovation & Skills, and the Foreign & Commonwealth Office), accept liability for any errors, omissions or misleading statements, and no warranty is given or responsibility accepted as to the standing of any individual, firm, company or other organisation mentioned. Published 2011 by UK Trade & Investment. Crown Copyright © You may reuse this information (not including logos, images and case studies) free of charge in any format or medium, under the terms of the Open Government Licence. To view this licence, visit www.nationalarchives.gov.uk/doc/open-government- licence/ or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gsi.gov.uk . This publication is also available from our website at www.ukti.gov.uk or for more information please telephone +44 (0)20 7215 8000. UK Trade & Investment Sector briefing: Biotech & Pharmaceutical opportunities in Singapore
Posted: 21 August 2011, last updated 21 August 2011

See more from Medical, Health and Cosmetics Products in Singapore

Expert Views    
Biotechnology & Pharmaceutical Opptys   By UK Trade & Investment
Biotechnology & Pharmaceutical Opportunities in Singapore   By UK Trade & Investment
Healthcare Opportunities   By UK Trade & Investment
Hot Tips    
Singapore IT Opportunities in Healthcare Sector   By U.S. Commercial Service Singapore
Healthcare Technologies Resource Guide   By U.S. Commercial Service